MARKET

TLSA

TLSA

Tiziana Life Sciences Ltd Com
NASDAQ
0.5699
-0.0406
-6.65%
Pre Market: 0.5501 -0.0198 -3.47% 08:16 11/16 EST
OPEN
0.6000
PREV CLOSE
0.6105
HIGH
0.6292
LOW
0.5655
VOLUME
2
TURNOVER
0
52 WEEK HIGH
1.900
52 WEEK LOW
0.5655
MARKET CAP
72.96M
P/E (TTM)
-2.7964
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TLSA last week (1109-1113)?
Weekly Report · 4h ago
Tiziana Life Sciences Ltd to Present at the Jefferies Global Healthcare Conference 2026
NASDAQ · 3d ago
Tiziana Life Sciences Announces Jefferies Healthcare Conference Presentation
TipRanks · 3d ago
BTIG Sticks to Their Buy Rating for Tiziana Life Sciences (TLSA)
TipRanks · 6d ago
Tiziana Life Sciences Ltd Highlights Positive Phase 2a INFORM-MS Topline Results and 12-Week Clinical Benefits of Intranasal Foralumab
NASDAQ · 6d ago
Tiziana Life Sciences Highlights INFORM-MS Phase 2a Results in KOL Call Update
TipRanks · 6d ago
Tiziana Life Sciences Highlights Phase 2a INFORM-MS Success For Intranasal Foralumab, Showing Reduced Neuroinflammation And Improved Fatigue In Secondary Progressive MS
Benzinga · 6d ago
Tiziana Life Sciences Ltd to Present at BIO-Europe 2026 and Host KOL Webcast
NASDAQ · 6d ago
More
About TLSA
Tiziana Life Sciences Ltd. is a biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Its clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer’s, and Amyotrophic lateral sclerosis. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.

Webull offers Tiziana Life Sciences Ltd - ADR stock information, including NASDAQ: TLSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLSA stock methods without spending real money on the virtual paper trading platform.